CD BioGlyco provides integrated Technologies for HMO Production. Our advanced technology platforms and high-quality services will fully meet your needs. We have the confidence to be your essential research assistant in the field of glycobiology.
Human milk oligosaccharides (HMOs) are a structurally distinct class of glycans that are present in human milk in a concentration range depending on the stage of lactation. These oligosaccharides are unique to breast milk and they are involved in the development and protection of the newborn. They are not digested by intestinal enzymes and reach the large intestine intact, where they stimulate the growth of healthy gut bacteria. In addition, human milk oligosaccharides are known to prevent pathogens from binding to their receptors by acting as soluble ligands, and they are thought to serve as nutrients for early brain development in infants.
LNnFP V is a neutral pentasaccharide naturally present in human breast milk. It is an important class of HMOs. The chemical structure is shown in Fig.1.
Fig.1 Chemical structure of LNnFP V. (CD BioGlyco)
Only a few HMOs have been produced using enzyme-catalyzed processes, and the synthesized HMOs are limited to those with relatively simple structures. Mammalian enzymes have been successfully characterized and several glycosyltransferases purified from human milk.
Bacteria are a rich source of glycosyltransferases, CD BioGlyco provides advanced technology to synthesize LNnFP V and glycoconjugates present on the surface of the human body through bacterial expression systems. Bacteria express a variety of glycosyltransferases that are responsible for building different lipopolysaccharide (LPS) and capsular polysaccharide structures. Recombinant bacterial glycosyltransferases have been increasingly used for the synthesis of several HMOs structures in enzymatic, chemoenzymatic, whole-cell, and live-cell approaches. For the technology of enzymatic synthesis of oligosaccharides, please refer to Production of HMO by Chemoenzymatic Methods.
Besides, CD BioGlyco provides a variety of available techniques for HMO Profiling: After designing the protocol, we use appropriate methods and conditions to collect and store LNnFP V. After pretreatment and labeling of the samples, the labeled oligosaccharides are separated and quantified by HPLC and analyzed by fluorescence detection.
CD BioGlyco has abundant experience in HMO production. We expect to become clients' research assistants in the research of LNnFP V analysis. If you are interested in our services, please contact us for more details without any hesitation.
Reference:
